目的：了解半剂量ＯＫＴ３能否逆转移植肾耐激素型急性排异（ＳＲ－ＡＲ）。方法：对发生ＳＲ－ＡＲ的肾移植受者，采用半剂量ＯＫＴ３治疗，并与全剂量ＯＫＴ３组对照，观察两组的ＳＲ－ＡＲ的逆转率及并发症发生率。结果：半剂量ＯＫＴ３组（ｎ＝１８）ＳＲ－ＡＲ逆转率为８８．９％，ＣＭＶ病发生率为３８．９％、发热６６．７％、寒颤２２．２％、恶心１６．７％、腹泻１１．１％，与全剂量ＯＫＴ３组（ｎ＝７）相比，两组ＳＲ－ＡＲ逆转率及上述各种发生率间差异均不显著，（Ｐ＞０．０５）。结论：半剂量ＯＫＴ３能逆转ＳＲ－ＡＲ。 Objective: To investigate whether half-dose OKT3 can reverse renal allograft hormone-resistant acute rejection (SR-AR). Methods: The renal transplant recipients with SR-AR were treated with OKT3 at a half dose and compared with the OKT3 group at full dose. The reversal rate of SR-AR and the complication rate of the two groups were observed. Results: The reversal rate of SR-AR in half dose OKT3 group (n = 18) was 88.9%, the incidence of CMV disease was 38.9%, fever was 66.7%, shivering was 22.2%, nausea was 16.7% Diarrhea 11.1%. Compared with the whole dose of OKT3 group (n = 7), there was no significant difference in the rate of SR-AR reversal between the two groups (P> 0.05). Conclusion: Semi-dose OKT3 can reverse SR-AR.